Original ArticleEfficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
Under a Creative Commons license
open access
Keywords
Selective PPARα modulator
Pemafibrate
K-877
Triglycerides
Dyslipidemia
Liver dysfunction
Fatty liver
Homocysteine
Renal dysfunction
Fibrates
Cited by (0)
This work was supported by Kowa Company, Ltd, who contributed in the study design, data collection, data analysis, data interpretation, and writing of the report.
© 2017 National Lipid Association.